Hikma Pharmaceuticals PLC

LSE HIK.L

Hikma Pharmaceuticals PLC EBITDA Margin for the year ending December 31, 2023: 27.51%

Hikma Pharmaceuticals PLC EBITDA Margin is 27.51% for the year ending December 31, 2023, a 42.78% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Hikma Pharmaceuticals PLC EBITDA Margin for the year ending December 31, 2022 was 19.27%, a -33.88% change year over year.
Hikma Pharmaceuticals PLC EBITDA Margin for the year ending December 31, 2021 was 29.14%, a 4.31% change year over year.
Hikma Pharmaceuticals PLC EBITDA Margin for the year ending December 31, 2020 was 27.94%, a 5.58% change year over year.
Hikma Pharmaceuticals PLC EBITDA Margin for the year ending December 31, 2019 was 26.46%, a 3.94% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

LSE: HIK.L

Hikma Pharmaceuticals PLC

CEO	Mr. Riad Ali Mishlawi
IPO Date	Nov. 1, 2005
Location	United Kingdom
Headquarters	1 New Burlington Place
Employees	9,100
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Consumer Packaged Goods Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Key trends

Past 5 years